NCT00511797View on ClinicalTrials.gov

SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Dysmenorrhea
Interventions
DRUG

SH T04740B

Drospirenone 1mg/EE 20µg (ß-CDC)

DRUG

SH T00186DF

Drospirenone 3 mg/EE 20µg (ß-CDC)

DRUG

SH T04740F

Drospirenone 2 mg/EE 20µg (ß-CDC)

DRUG

Placebo

Placebo

Trial Locations (12)

371-0024

Maebashi

650-0021

Kobe

663-8204

Nishinomiya

231-0861

Yokohama

612-0064

Kyoto

981-0933

Sendai

530-0013

Osaka

104-0061

Chuo-ku

192-0046

Hachiōji

156-0042

Setagaya-ku

157-0066

Setagaya-ku

171-0021

Toshima-ku

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY